サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1611097

フェニルケトン尿症治療市場規模、シェア、動向分析レポート：薬剤別、投与形態別、地域別、セグメント別予測、2025年～2030年

Phenylketonuria Treatment Market Size, Share & Trends Analysis Report By Drug (Kuvan, Palynziq), By Mode of Administration (Oral Administration, Parenteral Administration), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
フェニルケトン尿症治療市場規模、シェア、動向分析レポート：薬剤別、投与形態別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年11月15日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

フェニルケトン尿症（PKU）治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のフェニルケトン尿症治療市場規模は、2025～2030年にかけてCAGR 9.4％を記録し、2030年までに8億5,100万米ドルに達すると予測されています。

世界中でPKUの有病率が上昇していること、政府の規制が有利であることが、予測期間中の市場成長に拍車をかけると予想される要因です。

例えば、FDAによると、2018年、米国ではフェニルケトン尿症が約1万人から1万5,000人に1人の割合で罹患しています。さらに、Orphanetによると、欧州では新生児1万人に1人がPKUに罹患していると推定されています。この対象疾患は、イタリア、アイルランド、トルコなどの欧州諸国で高い頻度で発症しています。トルコでは約4,000人に1人がPKUと診断されていると推定されています。

民間と公的機関が実施する様々な啓発プログラムも、市場成長を促進すると予測されています。このようなプログラムを実施している組織には、SickKids、Children's Hospital of Wisconsin、CHOC Children's、Boston Children's Hospitalなどがあります。これらのプログラムは、PKU患者の精神的、発達的、身体的な健康を最適な状態に保つことを目的としています。

さらに、病気治療のための継続的な研究開発は、市場の成長を促進すると推定されています。例えば、Synlogic, Inc.のSYNB1618は第1/2a相臨床検査中であり、FDAからファストトラック指定も受けています。さらに、Rubius Therapeutics, Inc.、Retrophin, Inc.、Homology Medicines, Inc.などの他の企業も、経口療法、酵素療法、遺伝子療法などの新規療法を開発するための研究を行っています。

PKUの高額治療に対する償還施策が利用できることも、市場成長を後押しすると予測されています。クバンは現在、ドイツ、ベルギー、フランス、イタリア、オーストリアなど多くの欧州諸国で使用が承認され、償還されています。さらに、様々な組織による研究開発への資金提供プログラムの増加が市場を牽引すると予測されています。例えば、National PKU Allianceは、PKUの管理と治療の進歩を促進するのに役立つ研究プロジェクトに資金を提供しています。

フェニルケトン尿症治療市場レポートハイライト

  • Palynziqは2024年に67.9%の最大シェアを占め、予測期間中も大幅なCAGR成長が見込まれます。
  • 2024年のフェニルケトン尿症治療市場は、確立された医療インフラの存在、高い医療費、有利な政府規制により北米が支配的でした。
  • 欧州は、PKU新薬開発のための研究開発活動の活発化により、予測期間中に最も速いCAGRを示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 フェニルケトン尿症治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 フェニルケトン尿症治療市場：医薬品ビジネス分析

  • 医薬品市場シェア、2024年と2030年
  • 医薬品セグメントダッシュボード
  • 市場規模と予測と動向分析、医薬品別、2018～2030年
  • クヴァン
  • パリンジク
  • その他

第5章 フェニルケトン尿症治療市場：投与方法ビジネス分析

  • 投与方法の市場シェア、2024年と2030年
  • 投与方法セグメントダッシュボード
  • 市場規模と予測と動向分析、投与方法別、2018～2030年
  • 経口投与
  • 非経口投与

第6章 フェニルケトン尿症治療市場：薬剤と投与方法による地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • BioMarin
    • Synlogic
    • Travere Therapeutics, Inc.
    • DAIICHI SANKYO COMPANY, LIMITED.
    • Codexis, Inc.
    • SOM BIOTECH
    • Homology Medicines, Inc.（Q32 Bio Inc.）
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global phenylketonuria treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 5 Global phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 6 North America Phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 8 North America phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 9 U.S. phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 10 U.S. phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 12 Canada phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Mexico phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Europe phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 18 UK phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 19 UK phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 20 Germany phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Germany phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 22 France phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 23 France phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 24 Italy phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 25 Italy phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 26 Spain phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Spain phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 28 Denmark phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 29 Denmark phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 30 Sweden phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 31 Sweden phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 32 Norway phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Norway phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 37 Japan phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 38 Japan phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 39 China phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 40 China phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 41 India phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 42 India phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 43 Australia phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 44 Australia phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 45 South Korea phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 46 South Korea phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 47 Thailand phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 48 Thailand phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Latin America phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 53 Brazil phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 54 Argentina phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 55 Argentina phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Phenylketonuria treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 59 South Africa phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 60 South Africa phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 63 UAE phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 64 UAE phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)
  • Table 65 Kuwait phenylketonuria treatment market, by drug, 2018 - 2030 (USD Million)
  • Table 66 Kuwait phenylketonuria treatment market, by mode of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Phenylketonuria treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug outlook (USD Million)
  • Fig. 10 Mode of administration outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Phenylketonuria treatment market dynamics
  • Fig. 13 Phenylketonuria treatment market: Porter's five forces analysis
  • Fig. 14 Phenylketonuria treatment market: PESTLE analysis
  • Fig. 15 Phenylketonuria treatment market: Drug segment dashboard
  • Fig. 16 Phenylketonuria treatment market: Drug market share analysis, 2024 & 2030
  • Fig. 17 Kuvan market, 2018 - 2030 (USD Million)
  • Fig. 18 Palynziq market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Phenylketonuria treatment market: Mode of administration segment dashboard
  • Fig. 21 Phenylketonuria treatment market: Mode of administration market share analysis, 2024 & 2030
  • Fig. 22 Oral administration market, 2018 - 2030 (USD Million)
  • Fig. 23 Parenteral administration market, 2018 - 2030 (USD Million)
  • Fig. 24 Phenylketonuria treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 MEA phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait Key country dynamics
  • Fig. 77 Kuwait phenylketonuria treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework
目次
Product Code: GVR-3-68038-310-2

Phenylketonuria Treatment Market Growth & Trends:

The global phenylketonuria treatment market size is expected to reach USD 851.0 million by 2030, registering a CAGR of 9.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of PKU across the world and favorable government regulations are the factors expected to spur the market growth over the forecast period.

For instance, according to the FDA, in 2018, phenylketonuria affected about 1 in 10,000 to 15,000 people in U.S. Furthermore, according to the Orphanet, it was estimated that 1 in 10,000 newborns in Europe is suffering from PKU. The target disease is highly prevalent in European countries, such as Italy, Ireland, and Turkey. It was estimated that around 1 in 4000 individuals in Turkey were diagnosed with PKU.

Various awareness programs conducted by private and public organizations are also projected to fuel market growth. Some of the organizations conducting such programs are SickKids, Children's Hospital of Wisconsin, CHOC Children's, and Boston Children's Hospital. These programs aim to promote optimal emotional, developmental, and physical health PKU patients.

Furthermore, continuous R&D for the disease treatment is estimated to enhance the market growth. For instance, Synlogic, Inc.'s SYNB1618 drug is undergoing Phase 1/2a clinical trials and also received fast-track designation from FDA. In addition, other companies, such as Rubius Therapeutics, Inc., Retrophin, Inc., and Homology Medicines, Inc. are also conducting research to develop novel therapies, such as oral, enzyme therapy, gene therapy.

Availability of reimbursement policies for high-cost treatments of PKU is also projected to boost the market growth. Kuvan is currently approved for use and reimbursed in many European countries, such as Germany, Belgium, France, Italy, and Austria. Furthermore, increasing number of funding programs for R&D by various organizations is anticipated to drive the market. For instance, the National PKU Alliance provides funding to research projects that helps in promoting advances in the management and treatment of PKU.

Phenylketonuria Treatment Market Report Highlights:

  • Palynziq accounted for the largest share of 67.9% in 2024 and is also expected to grow at a significant CAGR over the forecast period.
  • North America dominated the phenylketonuria treatment market in 2024 owing to the presence of well-established healthcare infrastructure, high healthcare expenditure, and favorable government regulations
  • Europe region is expected to exhibit the fastest CAGR over the forecast period owing to rising R&D activities for the development of new PKU drugs

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Mode of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Phenylketonuria Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Phenylketonuria Treatment Market: Drug Business Analysis

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Drug Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 4.4. Kuvan
    • 4.4.1. Kuvan market, 2018 - 2030 (USD Million)
  • 4.5. Palynziq
    • 4.5.1. Palynziq market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Phenylketonuria Treatment Market: Mode of Administration Business Analysis

  • 5.1. Mode of Administration Market Share, 2024 & 2030
  • 5.2. Mode of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Mode of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral Administration
    • 5.4.1. Oral administration market, 2018 - 2030 (USD Million)
  • 5.5. Parenteral Administration
    • 5.5.1. Parenteral administration market, 2018 - 2030 (USD Million)

Chapter 6. Phenylketonuria Treatment Market: Regional Estimates & Trend Analysis by Drug and Mode of Administration

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. U.S. phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. Canada phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. Mexico phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. UK phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. Germany phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. France phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. Italy phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Spain phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive insights
      • 6.5.7.4. Denmark phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework
      • 6.5.8.3. Competitive insights
      • 6.5.8.4. Sweden phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key country dynamics
      • 6.5.9.2. Regulatory framework
      • 6.5.9.3. Competitive insights
      • 6.5.9.4. Norway phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. Japan phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. China phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive insights
      • 6.6.4.4. India phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive insights
      • 6.6.5.4. Australia phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive insights
      • 6.6.6.4. South Korea phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive insights
      • 6.6.7.4. Thailand phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. Brazil phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Argentina phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive insights
      • 6.8.2.4. South Africa phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive insights
      • 6.8.3.4. Saudi Arabia phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework
      • 6.8.4.3. Competitive insights
      • 6.8.4.4. UAE phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key country dynamics
      • 6.8.5.2. Regulatory framework
      • 6.8.5.3. Competitive insights
      • 6.8.5.4. Kuwait phenylketonuria treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. BioMarin
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Synlogic
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. Travere Therapeutics, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. DAIICHI SANKYO COMPANY, LIMITED.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. Codexis, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. SOM BIOTECH
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. Homology Medicines, Inc. (Q32 Bio Inc.)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives